Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALVR 
Allovir Inc (ALVR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/19/2025: ALVR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.3% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/19/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.25M USD | Price to earnings Ratio - | 1Y Target Price 1.2 |
Price to earnings Ratio - | 1Y Target Price 1.2 | ||
Volume (30-day avg) 12632 | Beta 0.74 | 52 Weeks Range 7.96 - 24.15 | Updated Date 03/30/2025 |
52 Weeks Range 7.96 - 24.15 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-13 | When Before Market | Estimate - | Actual -3.6389 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.53% | Return on Equity (TTM) -80.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -68813668 | Price to Sales(TTM) - |
Enterprise Value -68813668 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.37 | Shares Outstanding 115365000 | Shares Floating 30900075 |
Shares Outstanding 115365000 | Shares Floating 30900075 | ||
Percent Insiders 49.12 | Percent Institutions 42.95 |
Analyst Ratings
Rating 3 | Target Price 1.2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Allovir Inc
Company Overview
History and Background
Allovir, Inc. is a late-stage biopharmaceutical company founded in 2013. It is focused on developing and commercializing allogeneic T-cell therapies to treat and prevent viral diseases.
Core Business Areas
- Cell Therapy Development: Allovir focuses on developing allogeneic T-cell therapies targeting multiple viruses.
- Clinical Trials: The company conducts clinical trials to assess the safety and efficacy of its therapies.
Leadership and Structure
Dr. Diana Brainard is the CEO. The organizational structure consists of research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- Posoleucel: Posoleucel is Allovir's lead product candidate, a multi-virus specific T-cell therapy to treat infections associated with six common viruses (CMV, adenovirus, EBV, BKV, HHV-6, and VZV) in immunocompromised patients. Allovir has not launched Posoleucel yet, so does not have any market share, revenue from this product, or users. Competitors include antiviral drugs developed by companies like Vir Biotechnology and academic research institutions.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in biotechnology and increasing prevalence of viral infections in immunocompromised patients.
Positioning
Allovir is positioned as a leader in developing allogeneic T-cell therapies for viral diseases, targeting a broad range of viruses with a single product.
Total Addressable Market (TAM)
The estimated TAM for virus-associated diseases in immunocompromised patients is significant, potentially exceeding billions of dollars. Allovir aims to capture a substantial share of this market with Posoleucel and future therapies.
Upturn SWOT Analysis
Strengths
- Proprietary allogeneic T-cell therapy platform
- Broad-spectrum antiviral activity targeting multiple viruses
- Potential to address unmet medical needs in immunocompromised patients
Weaknesses
- Dependence on successful clinical trials and regulatory approval
- High development costs associated with cell therapies
- No currently marketed products
Opportunities
- Expanding into new viral indications and patient populations
- Strategic partnerships with pharmaceutical companies
- Advancements in cell therapy manufacturing technologies
Threats
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles and delays
- Unforeseen adverse events in clinical trials
Competitors and Market Share
Key Competitors
- VIR
- MRNA
- GILD
Competitive Landscape
Allovir's advantage lies in its allogeneic T-cell therapy platform targeting multiple viruses. However, it faces competition from companies developing antiviral drugs and other cell therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's progressing pipeline and expanding clinical programs.
Future Projections: Future growth is dependent on the successful commercialization of Posoleucel and the advancement of its pipeline. Analyst estimates vary but generally forecast significant revenue growth upon approval and launch of Posoleucel.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 trials for Posoleucel and expanding its pipeline through preclinical research.
Summary
Allovir is a clinical-stage biopharmaceutical company with a promising allogeneic T-cell therapy platform. The company's success hinges on the clinical success and eventual commercialization of Posoleucel. A key risk is the high attrition rate in clinical trials and competition from established pharmaceutical companies. The company has a strong technical platform but needs regulatory approval to generate revenue.
Similar Companies
- VIR
- MRNA
- GILD
- VRTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allovir Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-07-30 | CEO, President, CFO & Director Mr. Vikas Sinha C.A., CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.allovir.com |
Full time employees 6 | Website https://www.allovir.com | ||
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.